resisttb
- Jan 19
- 1 min read

Price reduction paves the way for expanded access to highly effective MDR-TB

Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.

Recent Posts

See All

Why is a curable disease allowed to kill millions?

John Green, the author of several books and a longtime supporter of Partners in Health, discusses his time visiting Sierra Leone’s Lakka Government Hospital, a tuberculosis treatment center. He talks

International consensus highlights the importance of molecular testing for MDR-TB

A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibio

Sweet advance for treatment of children with multi-drug resistant TB

Children with multi-drug resistant tuberculosis (MDR-TB) undergo months of life-saving treatment including many doses of foul-tasting medications, which caregivers often struggle to prepare and admini